Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma

@inproceedings{Kurai2012TherapeuticAE,
  title={Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma},
  author={Jun Kurai and Hiroki Chikumi and Kiyoshi Hashimoto and Miyako Takata and Takanori Sako and Kosuke Yamaguchi and Naoki Kinoshita and Masanari Watanabe and Hirokazu Touge and Haruhiko Makino and Tadashi Igishi and Hironobu Hamada and Seiji Yano and Eiji Shimizu},
  booktitle={International journal of oncology},
  year={2012}
}
Epidermal growth factor receptor (EGFR) is commonly overexpressed in malignant pleural mesothelioma (MPM). Cetuximab is a chimeric mouse-human antibody targeted against EGFR and induces potent antibody-dependent cellular cytotoxicity (ADCC). The action of cetuximab against MPM cells has not been well studied. Therefore, in this study, we investigated the antitumor activity of cetuximab against MPM cell lines, particularly with respect… CONTINUE READING
4 Citations
62 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 62 references

Similar Papers

Loading similar papers…